Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Construction in Progress (2022 - 2025)

Apyx Medical (APYX) has disclosed Construction in Progress for 4 consecutive years, with $162000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Construction in Progress fell 74.49% year-over-year to $162000.0, compared with a TTM value of $162000.0 through Dec 2025, down 74.49%, and an annual FY2025 reading of $162000.0, down 74.49% over the prior year.
  • Construction in Progress was $162000.0 for Q4 2025 at Apyx Medical, down from $635000.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $635000.0 in Q4 2024 and bottomed at $162000.0 in Q4 2025.
  • Average Construction in Progress over 4 years is $463571.4, with a median of $507000.0 recorded in 2022.
  • The sharpest move saw Construction in Progress surged 58.75% in 2024, then plummeted 74.49% in 2025.
  • Year by year, Construction in Progress stood at $507000.0 in 2022, then dropped by 21.1% to $400000.0 in 2023, then soared by 58.75% to $635000.0 in 2024, then plummeted by 74.49% to $162000.0 in 2025.
  • Business Quant data shows Construction in Progress for APYX at $162000.0 in Q4 2025, $635000.0 in Q4 2024, and $400000.0 in Q4 2023.